Moffitt Cancer Center shared on LinkedIn:
“In a packed ASH24 session, Doris Hansen, presented a comprehensive analysis of pre-treatment biomarkers associated with toxicity and durable response in idecabtagene vicleucel therapy for relapsed/refractory Multiple Myeloma patients.
Pre-treatment disease burden and inflammation pose a high risk for ICANS, whereas higher cell doses associated with high grade CRS.
Pre-treatment M-MDSCs and markers of T cell exhausted associate with reduced CAR-T expansion. DR was linked to lower PCB and favorable BM profiles: higher CD4:CD8 ratios, the presence of cytotoxic NK cells, and more stem central memory CD8+ T cells.
These findings provide insights into potential avenues for toxicity prevention and therapeutic optimization in high-risk patients.
Additional larger studies are warranted with longer follow-up to understand the complex relationships between inflammation, immunity, toxicity and efficacy among RRMM patients treated with idi-cel.”
